论文部分内容阅读
为观察低强度激光血管内照射（ＩＬＬＬＩ）循环血对恶性肿瘤患者化疗期间免疫水平的影响，总结恶性肿瘤患者化疗期间辅以Ｈｅ－Ｎｅ激光ＩＬＬＬＩ的２４例和对照同期未行ＩＬＬＬＩ的２４例，以血清白细胞介素２受体（ＳＩＬ－２Ｒ）为观察指标，比较两组患者ＳＩＬ－２Ｒ水平的变化及其差异。实验结果显示，化疗辅以ＩＬＬＬＩ的实验组治疗后，９例（占３７．５％）ＳＩＬ－２Ｒ水平下降，化疗前后的均值分别为５０３．３３３ｕ／ｍｌ和５５８．０４２ｕ／ｍｌ。对照组化疗后２４例（占１００．０％）ＳＩＬ－２Ｒ水平上升，化疗前后的均值分别为４９３．６２５ｕ／ｍｌ和７４４．０００ｕ／ｍｌ。经统计学处理，实验组化疗前后比较，ｔ＝１．２３１，Ｐ＞０．０５；对照组化疗前后比较，ｔ＝１２．１７７，Ｐ＜０．００１。两组间比较，化疗前ｔ＝０．１６１，Ｐ＞０．０５；化疗后ｔ＝２．８３０，Ｐ＜０．０１。提示，ＩＬＬＬＩ可缓冲恶性肿瘤患者化疗期间ＳＩＬ－２Ｒ水平的急剧上升。
To observe the effect of low-intensity laser intravascular irradiation (ILLLI) circulating blood on the immune response of patients with malignant tumor during chemotherapy, 24 patients with malignant tumor who were treated with He-Ne laser ILLLI during the chemotherapy and 24 patients without the control ILLLI during the same period were summarized, Serum interleukin 2 receptor (SIL-2R) was used as an index to compare the changes of SIL-2R levels and their differences between the two groups. The experimental results showed that the levels of SIL-2R in 9 cases (37.5%) decreased after chemotherapy with ILLLI, and the mean values before and after chemotherapy were 503.333u / ml and 558.042u / ml, respectively. In the control group, SIL-2R levels increased in 24 (100.0%) patients after chemotherapy, with mean values of 493.625u / ml and 744.000u / ml before and after chemotherapy, respectively. Statistically, the experimental group compared before and after chemotherapy, t = 1.231, P> 0.05; before and after chemotherapy in the control group, t = 12.177, P <0.001. Before treatment, t = 0.161, P> 0.05; t = 2.830 after chemotherapy, P <0.01. It is suggested that ILLLI can buffer the sharp increase of SIL-2R level in patients with malignant tumor during chemotherapy.